PR Newswire
CRANFORD, N.J. , Sept. 6, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in two investor conferences in September 2023 . Citius Chairman and CEO Leonard Mazur will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023 , and at the Sidoti Small-Cap Virtual Conference on Wednesday, September 20, 2023 .
H.C. Wainwright Conference Details:
Presentation: | 2:00 pm ET on September 11, 2023 |
Location: | Lotte New York Palace Hotel, New York City |
R egistration: | A vailable on the conference website . |
1x1 meetings: | Requests available upon registration or by contacting Citius Investor Relations . |
| |
Webcast: |
Sidoti Conference Details:
Presentation: | 2:30 pm ET on September 20, 2023 |
Location: | Virtual |
R egistration: | A vailable on the conference website . |
1x1 meetings: | Requests available through a Sidoti representative. |
About Citius Pharmaceuticals, Inc.
Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company's diversified pipeline includes two late-stage product candidates, Mino-Lok ® , an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections, which is currently enrolling patients in a Phase 3 Pivotal superiority trial, and LYMPHIR™, a novel IL-2R immunotherapy for an initial indication in CTCL. Mino-Lok was granted Fast Track designation by the FDA. LYMPHIR received orphan drug designation by the FDA for the treatment of CTCL and PTCL. At the end of March 2023 , Citius completed enrollment in its Phase 2b trial of CITI-002, a topical formulation for the relief of hemorrhoids. For more information, please visit www.citiuspharma.com .
Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113
SOURCE Citius Pharmaceuticals, Inc.